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1. Introduction
Aged kidneys perform worse after transplantation
Aging is the main risk factor for the development of age-related chronic diseases, which, in turn, pose a major burden for health care services and society [1] [2] [3] [4] [5] . This also holds true for kidney function. Age associated decline in kidney function can be accelerated by diabetes, hypertension and kidney diseases resulting in chronic kidney disease (CKD) [6, 7] . With an estimated prevalence between 11 and 13% worldwide, CKD is a major age-related disease [6, 8] . The treatment of CKD is mainly designed around targeting underlying causes such as inflammation, hypertension or obesity. Unfortunately, these only rarely restore primary kidney function [9] .
The further decline of kidneys suffering from CKD can lead to end stage renal disease (ESRD), which is characterized by such loss of renal function that patients are in need of kidney replacement therapy such as dialysis or the more favorable kidney transplantation [7, 10, 11] . This has come at a cost, as due to the continuous increase in population age, not only the incidence of ESRD has increased, but consequently also the demand for donor kidneys, leading to a shortage of suitable donor kidneys. To meet the required demand, kidneys from extended criteria donors are now accepted, including those from old donors [10] . This in turn, has created a new layer of complications. Kidney transplants from aged (65+ years) donors are more vulnerable to ischemic injury, suffer more from delayed graft function and have a lower graft survival compared to kidneys from younger donors [12] [13] [14] [15] . Also at the side of the recipient, old age is a complicating factor as aged patients are more vulnerable to dialysis-associated side effects and have a reduced survival rate after organ transplantation [16] . Finally, the transplantation procedure itself is a source of damage, which further accelerates the aging of the organ. This is delineated by the increased numbers of aged (senescent) cells, decreased function and increase of interstitial fibrosis (IF) and tubular atrophy (TA), as seen both in humans and model organisms such as mice following ischemia reperfusion injury (IRI) and transplantation [17, 18] . Therefore, profit could be gained by tackling aging in old CKD patients and aged kidney donors as well as patients that have undergone kidney transplantation.
As aging is associated with poor kidney function, and IRI accelerates aging, advances in anti-aging research might provide new insights and treatment options to improve the outcome of kidney transplantation. To convert these findings to transplantation research, it is important to understand what drives aging on a cellular level.
Aging causes senescence and an associated pro-inflammatory phenotype
Aging can be described as the decline of physiological integrity due to an accumulation of damage and deterioration of protein and organelle function [3] . Whereas damaged proteins and organelles can be restored or replaced, cells only contain one copy of their DNA and therefore unresolved DNA damage could have permanent deleterious consequences. Fortunately, most DNA damage can be repaired by specialized DNA damage repair mechanisms [19] . However, as these are not perfect, there is a chronic build-up of unresolved damage in time. This can accelerate cellular aging and in parallel lead to mutations that are potentially oncogenic [19] . To prevent the passage of DNA damage to daughter cells, the affected cells can undergo cell intrinsic cell death (apoptosis) or enter a state of permanent cell cycle arrest, called senescence [20, 21] . Whereas critical levels of DNA damage are considered a major cause for senescence induction, several other stimuli have also been described, such as telomere shortening, high levels of reactive oxygen species (ROS), oncogenic mutation, chromatin remodeling and mitochondrial dysfunction [22] . Regardless of its cause, senescence is permanent and can independently be enforced by persistent upregulation of the cyclin-dependent kinase (CDK) inhibitors p16 Ink4a or p21 Cip1 , the latter in a p53 dependent manner (Fig. 1 ). These force a permanent cell cycle arrest by impairing the activity of CDK's that are required for progression through the G1/S phase of the cell cycle [22] [23] [24] . The establishment of senescence is a multi-step process that can take several days to complete [25] .
A permanent cell cycle arrest is not the only characteristic of senescent cells. In the majority of cases, senescent cells develop a phenotype in which they permanently secrete a plethora of factors such as proinflammatory cytokines and chemokines (i.e. interleukins-6 (IL-6), −8, −1␣/␤), matrix metalloproteinases (i.e. MMP-1, −3, −10) and growth factors [26, 27] . The secretion of these factors by senescent cells is known as the senescence associated secretory phenotype (SASP). For a complete list of SASP factors and their function, we refer the readers to Coppé et al. (2010).
Through the SASP, senescent cells permanently impair tissue function during aging
Due to the secretory phenotype, senescent cells can have a diverse impact on their microenvironment. This can be beneficial, but only when present in a transient setting, e.g. during conditions of acute wound healing where some SASP factors such as plateletderived growth factor-AA (PDGF-AA) aid in wound closure [28] . Similarly in models for cirrhosis-induced liver fibrosis or during certain stages of embryonic development the transient presence of senescent cells can be beneficial [22, 29] . In contrast, senescent cells can cause severe problems when they exist permanently and their chronic secretion of SASP factors can have long term detrimental consequences. Fortunately, the secretion of cytokines and chemokines by senescent cells can attract immune cells and as such, the SASP primes senescent cells for degradation, especially by natural killer cells and other leukocytes [27, 30] . However, during aging the efficiency of the immune system declines, impairing the eradication of SASP expressing senescent cells [22, 31] . The gradual loss of senescent cell immune surveillance and the accumulation of damage with age, leads to increased numbers of senescent cells during aging. Importantly, immune surveillance in transplant recipients is also long-term suppressed with immune suppressive drugs to prevent allograft rejection [32, 33] . Thus, the ineffective clearance of senescent cells by the immune system leads to their increase in aged tissues and transplanted kidneys which can ultimately impair organ integrity.
Through SASP, accumulated senescent cells contribute to age associated low grade chronic inflammation (inflammaging) [34] . Inflammaging is a risk factor for age related diseases, as most of them have an inflammatory pathogenesis. Indeed, senescent cells are found at sites of age related pathologies such as glomerular disease, chronic allograft nephropathy, osteoarthritis, atherosclerosis and, ironically, cancer [20, 22, [35] [36] [37] .
Furthermore, due to the inability of senescent cells to replace other damaged cells during wound healing, senescence reduces the regenerative capacity of tissues. This is particularly harmful in kidney tubules, as replacement of damaged tubular epithelial cells by surviving counterparts, is impaired when these are in a chronic cell cycle arrest [38] . Furthermore, senescent cells can invoke pluripotency in their neighboring cells [39] . As we reasoned before, senescent cells may thus impair tissue rejuvenation by enforcing a permanent state of stemness, which has been coined as the senescence stem-lock model for aging [40] . In this model, the persistent secretion of SASP factors as IL-6 invokes a state of pluripotency in neighboring cells. As the SASP is persistent, so is this remodeling event and at times of need, differentiation of these cells is impaired, hampering tissue rejuvenation. Taken together, the impact of senescent cells on tissue integrity depends on the moment and duration of their existence. By aiding in an acute manner during cutaneous wound repair and through the prevention of potential neoplastic cell proliferation, senescence can be regarded as beneficial. But, whenever our immune system fails to remove these cells, chronic SASP secretion impairs proper tissue function and regeneration, leading to a decline in organ function as seen with increasing age. How senescence affects tissue function at different stages of renal transplantation will be discussed next.
Senescent cells impair immediate and long-term transplant outcome

Natural aging causes senescence and reduces kidney function
The growing shortage of kidney donors has led to the utilization of marginal organs, such as aged donor kidneys. Besides reduced filtering capacity, aged donor kidneys show delayed graft function and reduced graft survival time [12, 13] . This is, at least in part, caused by aged kidneys being more vulnerable to ischemia reperfusion injury (IRI) [12, 14, 15] . These processes cause a strong cellular oxidative stress response, resulting in impaired metabolism, inflammation and cell death [38] . In turn, these contribute to delayed graft function, graft rejection, fibrosis and acute or chronic kidney failure [41] . Senescent cells may be a prime culprit of these effects as they are known to reduce tissue regeneration, induce chronic inflammation and can enhance oxidative stress levels, stacked upon the levels caused by IRI [27, 38] . Indeed, elevated mRNA expression levels of several potent senescence markers such as p21 Cip1 and p16 Ink4a in pre-transplant biopsies correlate with poor outcome of renal transplantation [42] [43] [44] . Therefore, aged donor kidneys might benefit from strategies that remove senescent cells to improve their resistance against IRI and improve transplant outcome.
Transplantation can amplify the senescence burden of grafted tissue
In addition to the natural build-up of senescence during aging, senescence can also be triggered actively when healthy cells are exposed to excessive amounts of damage, such as oxidative damage [22, 36] . Thus, it could be that the oxidative stress caused by IRI can further elevate senescence burden of the already affected donor kidney. Deep biopsies of successfully transplanted organs are scarce, making it difficult to distinguish the levels of senescence after transplantation from those already present senescent cells in the donor organ, since superficial cortical biopsies do not reflect the level of senescence of the organ. Nonetheless, several studies show that transplantation induces senescence. For one, oxidative stress, as caused by IRI, was shown to be able to invoke senescence and lead to the accumulation of senescent cells in mice [41, 45, 46] . Moreover, renal IRI in mouse kidneys induced upregulation in protein or mRNA expression of senescence markers such as p21 Cip1 and p16 Ink4a [17, 47, 48] . Also, hypertension, a common sideeffect of transplantation can induce p16 Ink4a driven senescence in both humans and rats [49] . A similar increase in protein expression of p16 Ink4a was shown in post-transplant biopsies of rejected human kidneys [18] , at least suggesting that this also holds true for humans. Whereas in healthy subjects senescent cells are removed by the immune system, this will be hampered in transplant recipients due to their long term follow-up with immunosuppressive drugs [30, 32] . Thus, injuries associated with transplantation can induce senescence, which, on top of the already present levels of senescence in the donor tissue, cannot be removed by the immune system and may further contribute to the long-term damaging effects of transplantation.
Induction of temporary but not permanent senescence improves IRI outcome
Even though it is apparent that transplantation outcome can be improved by the removal of senescent cells before and after transplantation, the role of senescence during transplantation is more complicated. It is known that senescent cells have a benefi- Cip1 is activated to allow for DNA damage repair. This temporary cell cycle arrest can advance into senescence or apoptosis when DNA damage is irreparable. A knock out of the Cdkn1a locus, which codes for p21 Cip1 , reduces DNA damage repair and worsens IRI outcome. In contrast, knock out of the Cdkn2a locus, coding for p16 Ink4a , which still allows DNA damage repair via p53 and p21
Cip1 , improves IRI outcome. Therapeutic inhibition of CDK's using Palbociclib induces a temporary cell cycle arrest which improves outcomes after renal IRI. This might be caused by allowing DNA damage repair, without inducing senescence. Abbreviations: IRI; ischemia-reperfusion injury; CDK, cyclin-dependent kinase.
cial role during cutaneous wound repair through the secretion of SASP factors [28, 50] . However, it remains unclear whether senescent cells are also involved in renal repair [51, 52] . To assess the role for senescence and SASP during IRI, diverse studies with senescence pathway knock out mice have been performed, with both beneficial and disadvantageous outcomes (Fig. 1 ). There appears to be a discrepancy between which senescence pathway is interfered with versus disease outcome. For instance, mice carrying a homozygous deletion of the cdkn2a locus, which codes for the proteins p16 INK4a and p19 ARF , have decreased levels of apoptosis and IF/TA, improved epithelial regeneration and improved creatinine clearance after IRI, compared to wildtype (WT) littermates [17, 53] . Transplantation of a cdkn2a −/− kidney to a WT mouse also improves survival and reduces IF/TA compared to transplantation of a WT kidney, suggesting a beneficial effect for the inhibition of senescence induction during IRI [17] . In contrast, depletion of p21 Cip1 , which is also individually capable of inducing and maintaining senescence, aggravates ischemic injury compared to wild type mice, opposite to the effect of cdkn2a −/− mice [54, 55] . Thus apparently, the mode of cell cycle arrest induction is of importance to the outcome of kidney injury. This might be explained by differences in the mode of action through which p21 Cip1 and p16 Ink4a regulate cell cycle arrest. Oxidative stress due to IRI causes DNA damage, which activates the DNA damage response and p53. To allow for acute DNA damage repair, p53 rapidly induces p21 Cip1 transcription. P21 Cip1 induces an initial temporary cell cycle arrest, which is reversed when repair is completed and only becomes a permanent senescence-mediated arrest when the DNA damage is irreparable. P16 Ink4a , on the other hand, is activated in a much slower fashion, taking up to 4 days after the damaging insult, and triggers a permanent senescence-arrest [22] . Activation of p53 due to IRI, cannot allow for a temporary cell cycle arrest in p21 Cip1−/− mice, thus resulting in apoptosis or p16 Ink4a induced senescence, instead of DNA damage repair. The induction of a cell cycle arrest, without inducing senescence, which allows for DNA damage repair, might on the other hand improve IRI outcome. Excitingly, mimicking the mode of action of p16 Ink4a , only in a temporary fashion with the use of the CDK4/6 inhibitor Palbociclib, ameliorates the effects of IRI in mice by inducing a temporary cell cycle arrest [56] . Together, these data suggest that during transplantation-induced injury a temporary cell cycle arrest through p21 Cip1 and the subsequent DNA damage repair response, is favored over the induction of a permanent cell cycle arrest via p16 Ink4a . Therefore, anti-senescence treatment should focus on the removal of established senescent cells but not on preventing the induction of cell cycle arrest via p21 Cip1 .
Therapeutic interventions that prevent the induction of senescence and reduce SASP
Prevention of senescence induction after transplantation may improve outcome
To counteract the deleterious effects of senescence on transplantation success, an attractive solution would be to prevent accumulation of senescent cells in the first place. This is challenging for donor grafts in which the damage is already present, but it may be applicable to the recipient before and after transplantation (Fig. 2) . As senescence can both develop naturally over a prolonged period of time, or be actively induced by acute stress, different approaches may be necessary to prevent either. During IRI, any treatment that would prevent immediate oxidative stress and DNA damage might prevent the onset of senescence, whereas the prevention of aging associated senescence is closely related to a healthy lifestyle, such as regular exercise and a healthy diet [57, 58] . It has been 80 years, since the life extending effects of caloric restriction were shown on rats by the group of McCay [59] . This simple intervention that restricts dietary intake without causing malnutrition, promotes a plethora of health benefits. Even though it is inconvenient to maintain dietary restriction (DR) regiments in practice, many studies testing the effects of DR in humans and animals collectively showed that DR lowers total cholesterol, improves insulin sensitivity, lowers DNA damage and oxidative stress and reduces levels of senescence markers p16 Ink4a and p21 Cip1 [60] [61] [62] [63] [64] . The most profound features of DR on kidney function are improved filtration rates and reduced levels of fibrosis through a reduction in epithelial-to-mesenchymal-transition, which is recognized as a part of the kidney fibrosis mechanism during aging [60, 63] . Therefore, dietary restriction might be considered as a means to prolong graft function after transplantation in recipients. There are indications that DR may be beneficial to acute transplantation-mediated injuries as well. For instance, 3 days of preoperative fasting protects against IRI, even in aged and overweight mice [65] [66] [67] [68] . Dietary restriction increases expression of antioxidant defense markers and reduces expression of inflammatory markers through upregulation of the SIRT1, AMPK and downregulation of mTOR pathways [60, 67] . These are all interesting targets for lifespan extension and have exited researchers to pharmaceutically intervene with these processes to mimic the beneficial effects of dietary restriction, such as with Resveratrol, Metformin, Rapamycin and Nicotinamide mononucleotide [69] [70] [71] [72] [73] [74] [75] [76] . Together, these data argue that healthy lifestyle factors, as reduced dietary intake, may improve graft function and are important determinants in the long-term outcome after renal transplantation.
Reducing SASP can improve organ function
DR interferes with many processes, but one pronounced beneficial consequence of DR is the systemic reduction in chronic inflammation. Therefore, DR might not only be used to prevent the development of senescent cells during aging, but also to reduce the negative effects of the SASP from pre-existing senescent cells. As such, anti-inflammatory compounds might give similar beneficial effects on health. The use of broad spectrum anti-inflammatory drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit SASP and the production of prostaglandins, hormone-like lipids that are involved in inflammation [77, 78] . Arguments that such drugs may be beneficial in counteracting SASP-mediated effects on aging, are for instance provided by studies showing that NSAIDs improve the lifespan and reduce the age-associated disease burden of fast aging Lmna −/− progeria mice that suffer from excessive senescence load and the associated inflammation [79] . A complication with NSAID treatment however, is that long term treatment can lead to severe adverse effects on stomach and intestinal integrity, and vascular and renal deterioration [77] . Inhibition of the JAK/STAT pathway, which is important for SASP expression, reduces organ dysfunction and insulin resistance and even frailty in old mice [77, 80] . Unfortunately, also long term treatment with these compounds has deleterious effects as they can result in anemia and thrombocytopenia in humans [81] . Reduction of SASP might aid during and after renal transplantation. However, long periods of SASP reduction as accomplished by NSAID or use of JAK/STAT −inhibitors, are associated with complications on their own. Therefore, removing the root of the problem by eliminating senescent cells is preferred [73, 82] .
Therapeutic options to clear senescent cells
The discovery and development of anti-senescence compounds have been challenging researchers ever since the genetic removal of senescent cells was shown to improve healthspan and prolong lifespan [83, 84] . Anti-senescence compounds, also referred to as senolytics or senotherapeutics, are food for imagination as animal studies show they can reverse aging phenotypes, including improvement of kidney function [40] . For example, the genetic removal of senescent cells in aged INK-ATTAC mice, lowered blood urea nitrogen levels and attenuated glomerulosclerosis [84] .
As more and more anti-senescence drugs are being discovered or designed, it is important to optimize these to limit undesirable side effects. Senescence occurs throughout the body both diverse in cell types, mode of induction and maintenance and therefore they are a heterogeneous cell population, which makes it difficult to distinguish them from healthy cells and specifically target them. Furthermore, it is crucial that an anti-senescence therapy eliminates the cells. Non-lethal damage could cause them to acquire mutations that force them back into a state of proliferation, adding to the potential of becoming tumorigenic. One potent area of therapy-development would thus be to develop drugs that selectively force senescent cells into apoptosis. Recently several anti-senescence drugs have been identified or prospectively designed of which few have proven to have anti-senescence abilities in vivo ( Table 1) .
Regardless of the various reported anti-senescence compounds that may have more or less specific activity, two types of antisenescence drugs have proven to be potent and consistent and we will highlight these here as such: the pan-BCL family inhibitor ABT-263 (Navitoclax) and the FOXO4 D-Retro-Inverso peptide (FOXO4-DRI).
Navitoclax
As the viability of senescent cells relies on their resistance to apoptosis, an anti-apoptotic approach might selectively target senescent cells. The pan-BCL inhibitor ABT-263 is a BH-3 mimetic that can overcome BCL-2 family regulated prevention of apoptosis [85] . ABT-263, with the commercial name Navitoclax, has been shown to remove senescent cells in aged mice and promote rejuvenation of stem cells of several tissues, allowing for tissue regeneration [86, 87] . Unfortunately, apoptosis is not restricted to senescent cells, and interfering with this response may lead to adverse side-effects. Clinical trials with Navitoclax in cancer patients have revealed the dependence of platelets on BCL-2 and as a result ABT-263 reduces circulating platelet numbers and induces (severe) thrombocytopenia [88, 89] . Other BCL-2 family inhibitors such as A1331852 and A1155463 also proved to be toxic and did not target all senescent cells [90] . However, these side effects might be overcome with the use of targeted delivery of these compounds [91] .
FOXO4-DRI
Whereas the former drugs were discovered through multicompound screening approaches, a different approach was used for the generation of the recently described anti-senescence compound FOXO4-DRI [92] . In contrast to the other members of the Forkhead BOX O family, FOXO1 and 3, FOXO4 inhibition is well tolerated in cells and Foxo4 −/− mice show a relatively normal lifespan [93] [94] [95] . In senescent cells it was found that FOXO4 can serve as a binding partner of p53, preventing it from orchestrating its pro-apoptotic response [92, 96] . This interaction formed the basis for an innovative approach; the disruption of the specific p53 and FOXO4 interaction with a peptide allowing p53 induced apoptosis of senescent cells [40, 92, 97] .
Because p53 regulates many important processes in nonsenescent cells, inhibition of complete protein function is undesirable. The small interfering peptide FOXO4-DRI was designed to overcome this off-target sensitivity [40, 92] . FOXO4-p53 interacting foci were found to be markedly elevated in senescent cells, arguing the interruption of this interaction would largely affect senescent cells. Indeed, no side-effects on liver, kidney and hematopoietic function were reported after administration of FOXO4-DRI in naturally aged mice and in the fast aging model Xpd TTD/TTD . The removal of senescent cells with FOXO4-DRI in aged mice restored overall fitness and fur density. Importantly, a major restoration in renal function was observed in these aged mice as indicated by an average reduction in plasma urea concentration of over 50% and reduction of creatinine levels of almost 25%. This was accompanied by a reduction in senescence and inflammation markers in the kidney [92] . In line with the observations that genetic clearance of senescent cells in naturally aging mice can maintain renal filtering capacity, this study shows that renal function can be restored by senescent cell removal and that this is therapeutically feasible [84] . 
Quercetin and dasatinib
Though their efficacy has been challenged by several studies, dasatinib and quercetin were the first set of compounds described to have anti-senescence properties after a drug repurposing screen [92, 98, 99] . In combination, quercetin and dasatinib were reported to reduce senescent cell levels in vivo, improve cardiovascular function, pulmonary fibrosis, reduce frailty and extend healthspan [98, 100, 101] . Quercetin, a common flavonoid, appears most effective on senescent endothelial cells. Dasatinib, a chemotherapeutic, can eliminate senescent fat cell progenitors [98] . However, the combination of quercetin and dasatinib proved to be non-selective for senescent cells and also targeted healthy cells [98] , making it less suitable for therapeutic use in patients. Furthermore, it has been questioned to what extent quercetin and dasatinib are truly anti-senescence compounds, or whether they slow down the accumulation of cellular damage, which, in turn, may reduce senescence induction [92, 98] .
HSP-90 inhibitors
A different drug screening method focused on the inhibition of heat shock protein 90 (HSP90), which reduces viability in senescent human fibroblasts and senescent mouse stem cells [102] . HSP90 plays an important role in protein stabilization and degradation and is upregulated in many cancers but also senescent cells [102, 103] . HSP90 inhibitors, such as Geldanamycin and a more water-soluble successor 17-DMAG (Alvespimycin), have anti-proliferative effects on cancer, and were recently shown to have some anti-senescence activity as well [102] [103] [104] [105] . Treatment of fast aging ERCC /-mice with 17-DMAG delayed onset of several age-related disorders and improved overall healthspan [102] . However, it remains to be assessed whether HSP-90 inhibitors prevent the induction of senescent cells or truly eliminate them in vivo [102] . HSP-90 inhibitors can also target healthy cells and their use as cancer treatment in humans has been reported to give a side effect profile including renal failure, which has to be assessed when HSP90 inhibitors are considered as anti-senescence therapy [102, 106] .
The discovery and design of anti-senescence compounds has only just started. The use of designed, interaction modulating peptides will be a major opportunity to overcome the side-effects of non-specific anti-senescence agents, by interfering only with senescent cell specific interactions [92] . Although studies with antisenescence compounds in models of renal disease and injury are lacking, the reversal of age-associated decrease in renal function with the use of anti-senescence compounds gives high hopes for overcoming senescence associated deterioration of aged donor kidneys. Moreover, their use after transplantation may counteract transplantation induced damage, improving long term graft function (Fig. 2) .
Conclusions, discussion and future perspectives
As aged donor kidneys perform worse after transplantation and the transplantation associated injury accelerates aging of the graft, transplants might benefit from anti-aging therapies. The negative association between age and renal transplantation outcome has been explained here as a consequence of senescent cell abundance. Aging is caused by multiple deregulated processes, but it is clear that senescent cells are causal for aging due to their persistent secretory phenotype [84] . Through SASP, which mainly consists of pro-inflammatory factors, senescent cells negatively influence their environment and worsen transplantation outcome. Dietary restriction as well as several DR mimicking compounds prevent the onset of senescence and reduce inflammatory burden. These therapies might, in turn, improve graft survival if applied during initial periods after transplantation. As long-term interference with the SASP is impractical and leads to deleterious effects over time, a more realistic alternative would be to develop methods to eliminate senescent cells altogether before and after transplantation and, depending on the timing, during recovery from ischemiareperfusion injury. By now, there are two drugs that can potently eliminate senescent cells in vivo: Navitoclax and the less-toxic FOXO4-DRI. Their use in clinical studies for the purpose of targeting senescent cells to counteract age-related diseases still has to start. It will be exciting to see whether the promising findings on age related diseases in animal studies will hold true in human disease and in renal transplantation, and perhaps other organ transplants might benefit in the same manner. Several questions on anti-senescence therapies remain to be considered. The prospect of reversing signs of aging with anti-senescence compounds inspires people in search of everlasting youth, but it is important to recognize that senescent cells are not the sole cause of aging and side-effects of removing these cells have to be established [112] . So far, all anti-senescence compounds but FOXO4-DRI were repurposed from use in cancer treatment and have shown to cause side effects (Table 1) [88, 98, 106] . Perhaps targeted delivery of antisenescence compounds will overcome possible undesired effects in other organs [113] . Off-target effects of anti-senescence compounds on the function of the immune system are an important factor to take into account. With age, our immune-system declines in function and this influences immunosuppressive regimens in aged transplant recipients [15, 31, 114] . The anti-senescence compound Navitoclax was described to rejuvenate hematopoietic stem cells in mouse studies and it will be interesting to see what (other) anti-senescent compounds do with human immune system function. Perhaps these treatments boost rejuvenation of the aged immune system, which might demand altered immunosuppressive regimens in transplant recipients.
Anti-senescence compounds might also be applied in deceased kidney donors. Although it is not known at what time-interval antisenescence compounds induce apoptosis in vivo, the use of antisenescence compounds during machine reperfusion could allow for regeneration of the kidney during preservation.
It will be interesting to see whether interventions that reduce IRI, such as Sirolimus or machine reperfusion also prevent the induction of senescence [58] . And whether therapeutics that are nephrotoxic or worsen IRI outcome induce senescence. For example, the commonly used immunosuppressive agent Tacrolimus is known to be nephrotoxic, but it is not known whether Tacrolimus induces renal senescence in vivo [115] . Furthermore, immunosuppression with Tacrolimus might prevent clearance of senescent cells, which can accelerate aging in multiple tissues [33, 116] . If so, anti-senescence compounds could counteract immunosuppressive-associated toxicity and improve overall health of patients receiving immunosuppressive therapy.
In conclusion, the advances within the anti-aging research facilitate treatments for multiple (age-related) diseases, and may improve renal transplantation outcome. With evidence mounting that senescent cells are responsible for the decrease in renal function during aging and a complicating factor in renal transplantation, the reduction of senescent cell levels and hopefully accompanying improvement in kidney function after transplantation should become subject of future research.
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